

Fellype Carvalho Barreto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5456176/publications.pdf>

Version: 2024-02-01

62
papers

3,402
citations

218677

26
h-index

138484

58
g-index

65
all docs

65
docs citations

65
times ranked

4259
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney complications in 107 Fanconi anemia patients submitted to hematopoietic cell transplantation. <i>European Journal of Pediatrics</i> , 2022, 181, 715-723.	2.7	4
2	Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for Rare Diseases - Brazilian Society of Nephrology/2021. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2022, 44, 249-267.	0.9	6
3	Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN). <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2022, 44, 268-280.	0.9	3
4	In vitro anti-inflammatory effects of vitamin D supplementation may be blurred in hemodialysis patients. <i>Clinics</i> , 2021, 76, e1821.	1.5	5
5	Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. <i>Toxicology and Applied Pharmacology</i> , 2021, 414, 115412.	2.8	18
6	The benefits and challenges of family genetic testing in rare genetic diseases—lessons from Fabry disease. <i>Molecular Genetics & Genomic Medicine</i> , 2021, 9, e1666.	1.2	26
7	MO017 THERAPEUTICAL POTENTIAL OF ENZYME REPLACEMENT: NEW INSIGHTS AND PERSPECTIVES IN HUMAN ENDOTHELIAL CELLS TREATED WITH CHLOROQUINE. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
8	Renal Manifestations of Fabry Disease: A Narrative Review. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812098562.	1.1	18
9	Treatment of Osteoporosis in Chronic Kidney Disease. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 654-659.	0.9	0
10	Aluminum Intoxication in Chronic Kidney Disease. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 660-664.	0.9	8
11	Hypovitaminosis D in chronic kidney disease. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 639-644.	0.9	1
12	Update of Brazilian Guidelines for Treatment and Assessment of Chronic Kidney Disease – Mineral and Bone Disorders. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 613-614.	0.9	1
13	How do Uremic Toxins Affect the Endothelium?. <i>Toxins</i> , 2020, 12, 412.	3.4	35
14	Indoxyl Sulfate Contributes to Uremic Sarcopenia by Inducing Apoptosis in Myoblasts. <i>Archives of Medical Research</i> , 2020, 51, 21-29.	3.3	16
15	Letter to the Editor: “Nephrocalcinosis and Nephrolithiasis in X-Linked Hypophosphatemic Rickets: Diagnostic Imaging and Risk Factors” <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa013.	0.2	0
16	Rare inherited kidney diseases: an evolving field in Nephrology. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2020, 42, 219-230.	0.9	3
17	Vitamin D and chronic kidney disease: an uneasy relationship. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2020, 42, 386-387.	0.9	0
18	The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2019, 41, 336-344.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Strategies for Phosphate Control in Patients With CKD. <i>Kidney International Reports</i> , 2019, 4, 1043-1056.	0.8	74
20	Endothelial Microparticles in Uremia: Biomarkers and Potential Therapeutic Targets. <i>Toxins</i> , 2019, 11, 267.	3.4	19
21	Sevelamer reduces endothelial inflammatory response to advanced glycation end products. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 89-98.	2.9	21
22	A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women. <i>Nephron</i> , 2018, 138, 147-156.	1.8	12
23	The effect of vitamin D and zoledronic acid in bone marrow adiposity in kidney transplant patients: A post hoc analysis. <i>PLoS ONE</i> , 2018, 13, e0197994.	2.5	3
24	Macrothrombocytopenia, renal dysfunction and nephrotic syndrome in a young male patient: a case report of MYH9-related disease. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2018, 40, 198-200.	0.9	5
25	Enzyme replacement therapy for Anderson-Fabry disease. <i>The Cochrane Library</i> , 2017, 2017, CD006663.	2.8	71
26	The complexity of chronic kidney disease—mineral and bone disorder across stages of chronic kidney disease. <i>Kidney International</i> , 2017, 91, 1436-1446.	5.2	117
27	Comment on Indoxyl Sulfate—Review of Toxicity and Therapeutic Strategies. <i>Toxins</i> 2016, 8, 358. <i>Toxins</i> , 2017, 9, 142.	3.4	8
28	Uremia Retention Molecules and Clinical Outcomes. <i>Contributions To Nephrology</i> , 2017, 191, 18-31.	1.1	14
29	The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study. <i>PLoS ONE</i> , 2017, 12, e0174811.	2.5	29
30	Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. <i>PLoS ONE</i> , 2017, 12, e0173358.	2.5	71
31	SP332SEVELAMER CARBONATE REDUCES INFLAMMATION IN HUMAN ENDOTHELIAL CELLS EXPOSED TO ADVANCED GLYCATION END PRODUCTS (AGES). <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i201-i201.	0.7	0
32	Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening. <i>Nephron</i> , 2016, 134, 221-230.	1.8	26
33	The pitfall of treating low bone turnover: Effects on cortical porosity. <i>Bone</i> , 2016, 91, 75-80.	2.9	20
34	Uremic Toxicity-Induced Eryptosis and Monocyte Modulation: The Erythrophagocytosis as a Novel Pathway to Renal Anemia. <i>Blood Purification</i> , 2016, 41, 317-323.	1.8	31
35	Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. <i>Kidney International</i> , 2015, 87, 1039-1045.	5.2	59
36	SP424ERYPTOSIS INDUCED BY INDOXYL SULFATE IS RELATED TO OXIDATIVE STRESS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii518-iii518.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Peritoneal Delivery of Sodium Pyrophosphate Blocks the Progression of Pre-existing Vascular Calcification in Uremic Apolipoprotein-E Knockout Mice. <i>Calcified Tissue International</i> , 2015, 97, 179-192.	3.1	14
38	Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease. <i>Journal of Bone and Mineral Metabolism</i> , 2014, 32, 636-644.	2.7	4
39	Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure. <i>Kidney International</i> , 2013, 84, 491-500.	5.2	50
40	Effects of phosphate on vascular function under normal conditions and influence of the uremic state. <i>Cardiovascular Research</i> , 2012, 96, 130-139.	3.8	79
41	Estimated Glomerular Filtration Rate Is a Poor Predictor of the Concentration of Middle Molecular Weight Uremic Solutes in Chronic Kidney Disease. <i>PLoS ONE</i> , 2012, 7, e44201.	2.5	29
42	Pharmacotherapy of chronic kidney disease and mineral bone disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2627-2640.	1.8	27
43	Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2374-2383.	4.5	119
44	High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. <i>Atherosclerosis</i> , 2011, 215, 116-124.	0.8	23
45	Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3349-3357.	0.7	58
46	Estimated Glomerular Filtration Rate Is a Poor Predictor of Concentration for a Broad Range of Uremic Toxins. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1266-1273.	4.5	79
47	Prognostic Implication of Plasma Osteopontin Levels in Patients with Chronic Kidney Disease. <i>Nephron Clinical Practice</i> , 2011, 117, 363-372.	2.3	34
48	Inhibitors of vascular calcification as potential therapeutic targets. <i>Journal of Nephrology</i> , 2011, 24, 416-427.	2.0	14
49	The Circulating Inactive Form of Matrix Gla Protein Is a Surrogate Marker for Vascular Calcification in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 568-575.	4.5	251
50	The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2596-2602.	0.7	46
51	Vascular calcification is not an independent predictor of mortality in pre-dialysis adult patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2804-2805.	0.7	3
52	Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1183-1191.	0.7	371
53	Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. <i>Kidney International</i> , 2010, 77, 550-556.	5.2	242
54	Uraemic toxins for consideration by the cardiologistâ€”Beyond traditional and non-traditional cardiovascular risk factors. <i>Atherosclerosis</i> , 2010, 211, 381-383.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Fibroblast Growth Factor 23 in Hemodialysis Patients: Effects of Phosphate Binder, Calcitriol and Calcium Concentration in the Dialysate. <i>Nephron Clinical Practice</i> , 2010, 117, c74-c82.	2.3	59
56	Serum Ferritin Level Remains a Reliable Marker of Bone Marrow Iron Stores Evaluated by Histomorphometry in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 105-109.	4.5	46
57	Vitamin D Affects Survival Independently of Vascular Calcification in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1128-1135.	4.5	133
58	<i>Progress in Uremic Toxin Research</i> : Effects of Uremic Toxins on Vascular and Bone Remodeling. <i>Seminars in Dialysis</i> , 2009, 22, 433-437.	1.3	18
59	Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1551-1558.	4.5	740
60	Variant of Adynamic Bone Disease in Hemodialysis Patients: Fact or Fiction?. <i>American Journal of Kidney Diseases</i> , 2006, 48, 430-436.	1.9	20
61	Coronary calcification in hemodialysis patients: The contribution of traditional and uremia-related risk factors. <i>Kidney International</i> , 2005, 67, 1576-1582.	5.2	135
62	The renal osteodystrophy pattern in Brazil and Uruguay: An overview. <i>Kidney International</i> , 2003, 63, S54-S56.	5.2	45